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bUnidade de Transplante de Medula Óssea, Hospital de Clı́nicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil
c Serviço de Fisioterapia, Hospital de Clı́nicas de Porto Alegre (HCPA), Porto Alegre, RS, BrazilReceived 8 September 2019; received in revised form 28 August 2020; accepted 31 August 2020







Objective/Background: Hematopoietic stem cell transplantation (HSCT) is a treatment for
benign and malignant hematological diseases. These aggressive treatments cause reduced
levels of physical activity, decreased lung function, and worse quality of life. Alterations in pul-
monary function tests before HSCT are associated with the risk of respiratory failure and early
mortality. The objective of this study was to evaluate functional capacity and lung function
before and after HSCT and identify the predictors of mortality after 2 years.
Methods: A prospective cohort study was carried out with individuals with oncohematological
diseases. The evaluations were carried out in two moments during hospitalization and at hos-
pital discharge. Follow-up was carried out after 48 months. Assessments were carried out on 34
adults, using spirometry, manovacuometry, 6-Minute Walk Test (6MWT), Handgrip Strength
Test, and 30-Second Chair Stand Test (30-s CST).
Results: There was a statistically significant reduction for the variables in forced vital capac-
ity, forced expiratory volume predicted in the 1st second, Tiffeneau index, handgrip strength,
and distance covered (% predicted) on the 6MWT (p < .05). There was a significant difference inl (UFRGS),
Functional capacity, lung function, and muscle strength in patients 127the 30-s CST when individuals were compared according to the type of transplant. We found
that a 10% reduction in the values of maximum inspiratory pressure (MIP) can predict an
increased risk for mortality.
Conclusions: Individuals undergoing HSCT have reduced functional capacity, lung function, and
muscle strength during the hospitalization phase. Reduction in the values of MIP increases the
risk of nonrelapse mortality.
 2020 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
The Brazil’s National Cancer Institute estimates that
625,000 new cases of cancer will occur annually in Brazil
between 2020 and 2022 [1]. Hematopoietic stem cell trans-
plantation (HSCT) is a potentially curative treatment for a
variety of malignant and nonmalignant hematological disor-
ders [2–5]. Approximately 80 diseases at different stages
and age groups can benefit from this treatment method
[6]. Because of technological advances in transplantation
and treatment, HSCT has become relatively safe and its
applicability continues to expand [3].
The results of HSCT vary according to the baseline dis-
ease [5], type and intensity of conditioning, radiotherapy
[7,8], and type of transplantation [9,10]. In addition, com-
plications such as graft-versus-host disease [4], comorbidi-
ties related to previous treatments, and recipient age
influence the success of the procedure [11,12].
Pulmonary complications are frequent and affect the
success of autologous HSCT (auto-HSCT) or allogeneic HSCT
(allo-HSCT). Auto-HSCT presents fewer pulmonary compli-
cations as it does not require immunosuppressive therapy
[13]. Pulmonary infiltrates occur in 30–50% of HSCT recep-
tors, can have infectious or noninfectious origin, and con-
tribute significantly to pulmonary morbidity [14].
The underlying disease and aggressive treatment before
HSCT lead to a decline in health status. In the skeletal mus-
cular system, sarcopenia, fatigue, reduced muscle strength,
health-related quality of life, and consequently reduced
exercise capacity can occur [9,15–19]. These factors can
hamper the recovery of activities of daily living after hospi-
tal discharge [17].
The evaluation of pulmonary function and exercise
capacity before and after HSCT is essential in screening
and monitoring patients with a higher risk of mortality.
The 6-Minute Walk Test (6MWT) is commonly used to assess
the pre-HSCT functional capacity and can be considered a
predictor of post-HSCT mortality [20]. However, the factors
associated with mortality after HSCT are still not well-
established in the literature.
This study aims to verify alterations in functional capac-
ity, lung function, and peripheral muscle strength before
and after HSCT and to identify the predictors of mortality
after 2 years of HSCT.
Methods
This is a prospective cohort study involving adult patients
admitted to the bone marrow transplant sector at theHospital de Clı́nicas de Porto Alegre (HCPA) that are sched-
uled to receive HSCT. This study was carried out in accor-
dance with Resolution 466/12 of the National Health
Council and was approved by the hospital’s Research Ethics
Committee (No. 16–0255).
The study population consisted of adult patients, aged
over 18 years, with a hematological disease diagnosed by
complementary examinations. Patients with cardiac, ortho-
pedic, or trauma complications that limited the perfor-
mance of the functional test, as well as those with
recurrence of the disease were excluded.
After accepting to participate in the research and signing
the informed consent form, patients were evaluated within
the first 48 hours of hospitalization, mandatorily before
starting chemotherapy or cell infusion, and re-evaluated
at the time of hospital discharge. The monitoring of patients
was carried out through electronic medical records for
48 months after HSCT to assess the outcome of nonrecurring
mortality.
Follow-up of patients was performed using the electronic
medical record for 48 months after HSCT to assess the non-
relapse mortality outcome.
Functional capacity was evaluated using the 6MWT,
according to the guidelines published by the American Tho-
racic Society and European Respiratory Society [20].
Patients received standardized verbal stimuli and were
instructed to do as many laps as possible in a 6-minute per-
iod. The distance covered was recorded in percentage of
predicted value and the calculation was performed using
normality equations for Brazilian adults [21]. The pulmonary
function tests were performed with a computerized spirom-
eter (Master Screen, Jaeger version 4.31a; Jaeger, Würz-
burg, Germany) at the Pulmonary Physiology Unit of the
Pulmonology Service of HCPA. The test was carried out with
the patient in a sitting position, and conducted in accor-
dance with the Guidelines for Pulmonary Function Tests of
the Brazilian Society of Pulmonology and Tisiology. The val-
ues of forced vital capacity (FVC), forced expiratory volume
predicted in the 1st second (FEV1), and Tiffeneau index
(FEV1/FVC) were recorded. The values were expressed as
a percentage of the predicted value according to the refer-
ence equations for the Brazilian population [22]. Respira-
tory muscle strength was obtained using a device called a
digital manometer (Homed, Microhard MVD 300, version
1.0; Porto Alegre, Brazil), where it was possible to obtain
the values of maximum inspiratory pressure (MIP) and max-
imum expiratory pressure. The test was performed with the
patients seated, using a nasal clip to prevent air from escap-
ing during the maneuvers. At least three acceptable maneu-
vers (without air leak and lasting  2 seconds) and
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were performed. The highest value was computed and
expressed as a percentage of the predicted value [21].
We performed the 30-Second Chair Stand Test (30-s
CST) to assess lower limb strength [23]. Participants were
seated in a chair with their hips and knees at 90. The
upper limbs were crossed at the level of the wrists at chest
height. Patients were asked to sit down and rise up out of
the chair as many times as possible in a period of 30 sec-
onds. The result was determined by the maximum number
of repetitions performed correctly in the 30-second period
[24].
The handgrip strength was performed using a Dayhome
digital dynamometer (E-Clear, model EH101). The individual
should be seated with a 90 hip and knee flexion angle, erect
spine, adducted shoulders, elbow flexed at 90, and forearm
and wrist in a neutral position. The dominant limb was used,
according to the procedures of the American Society of
Hand Therapists [25]. Three maneuvers were performed,
with an interval of 20 seconds [26] and maximum contrac-
tion of 3–5 seconds [27]. The average value of the three
maneuvers (expressed in kilograms) was accepted as an
absolute value.
Body weight was checked using a Filizola electronic
scale. Height was measured with the digital scale anthro-
pometer. The body mass index (BMI) was obtained using
the formula BMI = weight (kg)/height2 (m), according to
the references established by the World Health Organization
[28].
Statistical analysis
The sample size was calculated using the WINPEPI program,
version 11.43. The calculated sample size of 32 individuals
had the ability to detect a 7.7% reduction between the
FEV1 averages before and after transplantation, considering
the standard deviation of the differences of 17.12 (as per
data from the pilot study carried out previously). A power
of 80% and a significance level of 5% were considered. Data
were analyzed using SPSS software version 18 (SPSS Inc.,
Chicago, IL, USA).
The primary outcome measure was FEV1. The secondary
outcomes were distance on the 6MWT, handgrip strength,
result of 30-s CST, MIP, maximum expiratory pressure, and
nonrelapse mortality without recurrence.
Quantitative variables were described by mean and stan-
dard deviation and categorical variables by absolute and rel-
ative frequencies.
In order to compare the parameters over time, general-
ized estimation equations model complemented by the least
significant difference test was applied.
To evaluate the effect of these variations in relation to
death, the regression model of Cox proportional hazards
(univariate and multivariate analyses) was used. The crite-
rion for entering the variable in the multivariate model is
that it should have a value of p < .20 in the univariate
analysis.
To obtain the best cutoff point for the MIP variation in
the prediction of death, the receiver operating characteris-
tic curve was used.The level of significance adopted was 5% (p < .05) and the
analyses were performed using SPSS version 21.0 (SPSS Inc.).
Results
Between September 2016 and June 2020, 45 patients were
hospitalized at the HCPA for HSCT. Two patients refused
to participate and nine others did not meet the inclusion cri-
teria because they were unable to complete the proposed
tests. The sample consisted of 34 adult patients, aged
18 years, who completed the assessments in the pre-HSCT
phase; 32 patients completed the post-HSCT assessment
and two did not complete the post-transplant assessments
because they died after receiving the HSCT in the hospital-
ization phase. Data on clinical and demographic character-
istics of the individuals in the sample who received HSCT
are presented in Table 1.
In the studied sample, multiple myeloma was the most
prevalent disease (32%) followed by non-Hodgkin lymphoma
(18%) and Hodgkin lymphoma (15%; Table 2).
The variables used in analysis were weight, BMI, lung
function, upper and lower limb muscle strength, distance
covered on the 6MWT, and respiratory muscle strength.
There was a statistically significant reduction in weight,
BMI, FEV1, FEV1/FVC, handgrip strength, distance covered
in the 6MWT (% predicted), and MIP (p < .05) following HSCT
(Table 3).
Individuals were stratified according to the type of HSCT
(allo- or auto-HSCT) in the pre- and post-transplant phases.
There was no significant difference between the different
types of transplant in clinical characteristics, exercise
capacity, and lung function (p > .05). Allo-HSCT showed a
significantly greater drop in the 30-s CST (p < .05; Table 4).
Univariate and multivariate Cox regression analyses were
performed to predict death according to the variables. The
multivariate analysis was adjusted in accordance with age,
donor status, cell source, radiation therapy, bone marrow
pick, and type of transplant. The variable that showed a sig-
nificant difference was MIP (p < .05). A reduction of 1% in
the value of MIP would increase the probability of death
by 5% (Table 5).
In the 2-year follow-up after HSCT, eight deaths
occurred. Among these, six occurred within the first
12 months and the others in the 2nd year of follow-up.
Assessment of survival time in 24 months according to
the MIP values presented. The data were adjusted according
to the variables, type of transplant and radiotherapy. The
results show that if there is a 10% reduction in MIP, the prob-
ability of non-recurring mortality increases by 14.4 times
(Fig. 1).
Discussion
A total of 34 individuals were included in this study;
among them, 32 completed post-HSCT assessments. As
much as 13 patients underwent allo-HSCT and 21
patients underwent auto-HSCT. The evaluation of the
acute phase after HSCT showed a significant decline in
lung function, exercise capacity, and peripheral and res-
piratory muscle strength. In the 2-year follow-up, eight
Table 1 Clinical and Demographic Characteristics of the Individuals Who Underwent HSCT.








Matched related 21 61.8
Matched unrelated 10 29.4
Haploidentical 3 8.8
Cells source
Bone marrow 9 26.5



















Note. HSCT = hematopoietic stem cell transplantation.
Table 2 Hematological Diseases of the Included Individuals.
Diagnostic Absolute frequency (N = 34) Relative frequency, %
Multiple myeloma 11 32
Non-Hodgkin lymphoma 6 18
Hodgkin lymphoma 5 15
Acute myeloid leukemia 3 9
Chronic myeloid leukemia 2 6
Myelodysplastic syndrome 2 6
Acute lymphocytic leukemia 2 6
Myelofibrosis 1 3
Aplastic anemia 1 3
POEMS syndrome 1 3
Note. N = absolute frequency sample; POEMS = polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin
changes; % = relative frequency sample.
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dictor of mortality.
Pulmonary complications are considered barriers for the
overall success of HSCT, and were an important cause of
morbidity and mortality [29–32]. Individuals with impaired
lung function before transplantation are at an increased riskof developing respiratory failure, increasing the risk of post-
transplant mortality [33]. In our study, there was a statisti-
cally significant reduction in lung function in the acute
phase after HSCT; however, this did not impact mortality.
Despite the reduction in lung function, the values remained
within the normal range, which may be the reason why
Table 3 Nutritional Characteristics, Lung Function, and Exercise Capacity of Pre- and Post-HSCT Patients.
Variable Pre-HSCT (N = 34) Post-HSCT (N = 32) 95% CI difference p
Mean ± SD Mean ± SD
Weight (kg) 78.1 ± 17.7 72.3 ± 14.6 –5.8 (–9.1 to –2.6) <0.001*
BMI (kg/m2) 27.7 ± 5.3 26.0 ± 4.3 –1.7 (–2.9 to –0.6) 0.002*
FVC (% predicted) 94.6 ± 13.8 89.5 ± 21.5 –5.1 (–10.5 to 0.3) 0.067
FEV1 (% predicted) 97.1 ± 16.9 88.1 ± 23.2 –9.0 (–15.5 to –2.5) 0.006*
FEV1/FVC (% predicted) 100.0 ± 11.3 92.1 ± 19.2 –7.9 (–15.1 to –0.7) 0.031*
Hand grip strength (kg) 29.5 ± 11.4 26.1 ± 10.9 –3.4 (–5.4 to –1.4) 0.001*
30-s CST (number of repetitions) 13.2 ± 4.4 12.2 ± 4.0 –1.0 (–2.2 to 0.3) 0.122
Distance 6MWT (% predicted) 73.0 ± 13.7 58.0 ± 21.5 –15.0 (–22.5 to –7.3) <0.001*
MEP (% predicted) 63.7 ± 19.1 57.9 ± 17.7 –5.8 (–10.3 to –1.4) 0.011*
MIP (% predicted) 56.5 ± 18.6 53.2 ± 17.4 –3.3 (–7.9 to 1.4) 0.171
Note. 30-s CST = 30-Second Chair Stand Test; 6MWT = 6-Minute Walk Test; BMI = body mass index; CI = confidence interval; FEV1 = forced
expiratory volume predicted in the 1st second; FVC = forced vital capacity; HSCT = hematopoietic stem cell transplantation;
MEP = maximum expiratory pressure; MIP = maximum inspiratory pressure; SD = standard deviation; % predicted = percentage of
predicted.
* Statistically significant values.
Table 4 Clinical Characteristics, Exercise Capacity, and Lung Function of Patients Who Underwent Allogenic or Autologous
HSCT.
Variable Allogenic transplant (n = 13) Autologous transplant (n = 21) p
95% CI (difference: post – pre) 95% CI (difference: post – pre)
Weight (kg) –10.1 (–18.3 to –1.8) –3.8 (–5.7 to –1.9) 0.149
BMI (kg/m2) –3.1 (–5.9 to –0.3) –1.2 (–1.9 to –0.4) 0.192
FVC (% predicted) –5.7 (–13.9 to 2.6) –4.8 (–11.7 to 2.1) 0.872
FEV1 (% predicted) –4.3 (–14.4 to 5.8) –11.9 (–20.1 to –3.7) 0.256
FEV1/FVC (% predicted) –0.1 (–9.7 to 9.4) –12.6 (–21.8 to –3.4) 0.066
Hand grip strength (kg) –5.5 (–10.1 to –0.9) –2.3 (–4.1 to –0.5) 0.209
30-s CST (number of repetitions) –3.6 (–6.0 to –1.3) 0.5 (–0.4 to 1.5) 0.001*
Distance 6MWT (% predicted) –12.2 (–24.0 to –0.4) –17.0 (–26.6 to –7.4) 0.533
MEP (% predicted) –7.1 (–13.3 to –1.0) –4.6 (–10.4 to 1.3) 0.125
MIP (% predicted) 2.7 (–3.3 to 8.6) 3.1 (–3.2 to 9.4) 0.921
Note. 30-s CST = 30-Second Chair Stand Test; 6MWT = 6-Minute Walk Test; BMI = body mass index; CI = confidence interval; FEV1 = forced
expiratory volume predicted in the 1st second; FVC = forced vital capacity; HSCT = hematopoietic stem cell transplantation;
MEP = maximum expiratory pressure; MIP = maximum inspiratory pressure; SD = standard deviation; % predicted = percentage of
predicted.
* Statistically significant value.
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month follow-up after HSCT.
A previous study carried out a follow-up of approximately
60 months after HSCT and found that changes in lung
function may also be present in asymptomatic individuals.
Therefore, performing pulmonary function tests often could
highlight which individuals may have pulmonary complica-
tions, such as the risk of pulmonary graft-versus-host dis-
ease [34,35].
In addition to spirometry, the evaluation of maximum sta-
tic respiratory pressures allows investigating the strength of
respiratory muscles [36]. In this study, MIP is considered a
predictor of mortality with a 1% reduction in the MIP value
increasing the probability of death by 5%. Previous studies
in pre- and post-HSCT individuals have also identified a reduc-tion inmuscle strength [37,38], but without finding an associ-
ation with mortality. In critically ill patients, respiratory
muscle weakness, especially MIP, is associated with worse
quality of life andmortality after hospital discharge [39–42].
In this study, we observed a significant reduction in hand-
grip strength in the allo- and auto-HSCT groups. The reduc-
tion in handgrip strength in patients with hematological
disease may be associated with functional deconditioning
[43]. Individuals who underwent HSCT showed a significant
loss (6%) of handgrip strength test at 1month after transplan-
tation; however, their strength recovered in the next
2 months in the absence of graft-versus-host disease [44].
The reduction in handgrip strength may be associated with
physical deconditioning and immobility during the hospital
stay.
Table 5 Univariate and Multivariate Cox Regression Analyses to Predict Death.
Variable Univariate analysis Multivariate analysis* p
HR (95% CI) HR (95% CI)
D Weight (kg) 0.97 (0.84–1.12) 1.02 (0.80–1.29) 0.895
D BMI (kg/m2) 0.96 (0.86–1.07) 0.93 (0.81–1.07) 0.286
D FVC (% predicted) 0.99 (0.95–1.03) 0.97 (0.91–1.04) 0.463
D FEV1 (% predicted) 0.99 (0.96–1.03) 0.98 (0.91–1.05) 0.575
D FEV1/FVC (% predicted) 1.01 (0.97–1.05) 0.97 (0.91–1.03) 0.268
D Hand grip strength (kg) 0.99 (0.95–1.05) 1.03 (0.95–1.11) 0.485
D 30-s CST (n. repetitions) 0.96 (0.92–1.01) 0.99 (0.92–1.08) 0.944
D Distance 6MWT (% predicted) 1.00 (0.97–1.03) 1.00 (0.97–1.03) 0.854
D MEP (% predicted) 1.00 (0.97–1.04) 0.99 (0.94–1.05) 0.789
D MIP (% predicted) 0.98 (0.95–1.01) 0.95 (0.90–0.99) 0.028**
Note. 30-s CST = 30-Second Chair Stand Test; 6MWT = 6-Minute Walk Test; BMI = body mass index; CI = confidence interval; FEV1 = forced
expiratory volume predicted in the 1st second; FVC = forced vital capacity; HR, hazard ratio; HSCT = hematopoietic stem cell trans-
plantation; MEP = maximum expiratory pressure; MIP = maximum inspiratory pressure; SD = standard deviation; % predicted = percentage
of predicted; D = difference post – pre.
* Adjusted by age, donor status, cell source, radiation therapy, bone marrow, and transplant type.
** Statistically significant value.
Functional capacity, lung function, and muscle strength in patients 131Fig. 1 Survival time 48 months after hematopoietic stem cell transplantation according to the presented values of maximum
inspiratory pressure (MIP).The 6MWT has been used in this population to assess
exercise capacity, which is considered a quick and easy test.
Jones et al. [45] evaluated 407 pre-HSCT individuals and
found that the distance covered on the 6MWT less than
400 m was associated with an increased risk of mortality
after the HSCT. These data differ from our findings because
we did not find any correlation between the 6MWT and mor-
tality despite the significant reduction in the distance cov-ered in the 6MWT after HSCT. Other studies confirm our
results that there is a significant reduction in functional
capacity after HSCT [46–51].
Our study had some limitations, such as the different
types of procedures, conditioning protocols, donor condi-
tion, prophylaxis and radiotherapy. In addition, there was
a wide age group among the participants (18 to 67 years
old). The diffusion capacity of carbon monoxide has not
132 T.C. Silva et al.been evaluated, although it is considered relevant in the
diagnosis of obliterating lung disease and in the identifica-
tion of pulmonary disease of the graft against the host,
both of which are the main complications related to
HSCT.
Conclusion
Based on our results, it can be concluded that adult patients
present a deterioration of the clinical condition after HSCT,
as evidenced by reduced pulmonary function, exercise
capacity, and muscle strength in the hospitalization phase.
Inspiratory muscle strength was considered a predictive
variable for nonrelapse mortality after HSCT. Therefore,
evaluations and ostensible follow-up in the hospitalization
phase for HSCT can assist in the early management of alter-
ations, avoiding complications and functional losses.
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REDOME, http://redome.inca.gov.br/doador/importancia-de-
ser-um-doador/
[7] Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al.
Defining the intensity of conditioning regimens: working
definitions. Biol Blood Marrow Transpl 2009;15:1628–33.
[8] Baumann FT, Zopf EM, Nykamp E, Kraut L, Schüle K, Elter T,
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